DNAJC13

Across TCGA pan-cancer cohorts, DNAJC13 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DNAJC13 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DNAJC13 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJC13 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where DNAJC13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.658	0.978	<.001	37	view →
HNSC	OS	Median	All	0.820	0.605	.005	13	view →
UCEC	DFS	Quartile	All	0.761	1.000	.006	8	view →
GBM	DFS	Tertile	All	0.256	0.486	.011	5	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
LUAD	DFS	Tertile	All	0.990	0.834	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DNAJC13–PDAC (OS)

Open the PDAC breakdown →